CA2967826C - A combination of ibudilast and riluzole and methods of using same - Google Patents

A combination of ibudilast and riluzole and methods of using same Download PDF

Info

Publication number
CA2967826C
CA2967826C CA2967826A CA2967826A CA2967826C CA 2967826 C CA2967826 C CA 2967826C CA 2967826 A CA2967826 A CA 2967826A CA 2967826 A CA2967826 A CA 2967826A CA 2967826 C CA2967826 C CA 2967826C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
ibudilast
riluzole
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967826A
Other languages
English (en)
French (fr)
Other versions
CA2967826A1 (en
Inventor
Kazuko Matsuda
Yuichi Iwaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CA2967826A1 publication Critical patent/CA2967826A1/en
Application granted granted Critical
Publication of CA2967826C publication Critical patent/CA2967826C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2967826A 2014-11-26 2015-11-24 A combination of ibudilast and riluzole and methods of using same Active CA2967826C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084879P 2014-11-26 2014-11-26
US62/084,879 2014-11-26
PCT/US2015/062456 WO2016085998A1 (en) 2014-11-26 2015-11-24 Combination of ibudilast and riluzole and methods of using same

Publications (2)

Publication Number Publication Date
CA2967826A1 CA2967826A1 (en) 2016-06-02
CA2967826C true CA2967826C (en) 2024-01-16

Family

ID=56074979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967826A Active CA2967826C (en) 2014-11-26 2015-11-24 A combination of ibudilast and riluzole and methods of using same

Country Status (9)

Country Link
US (3) US10258611B2 (enExample)
EP (1) EP3223815B1 (enExample)
JP (1) JP6827924B2 (enExample)
KR (1) KR102462638B1 (enExample)
CN (1) CN107205986A (enExample)
BR (1) BR112017010700A2 (enExample)
CA (1) CA2967826C (enExample)
ES (1) ES2891306T3 (enExample)
WO (1) WO2016085998A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530543A (ja) * 2018-07-22 2021-11-11 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. アルツハイマー病を処置するためのリルゾールプロドラッグの使用
CN112584831A (zh) * 2018-08-16 2021-03-30 拜奥海芬治疗学有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
ES2970996T3 (es) 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
EP4031135A4 (en) 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2375874A1 (en) 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
WO2004105756A2 (en) 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast

Also Published As

Publication number Publication date
JP2017535569A (ja) 2017-11-30
ES2891306T3 (es) 2022-01-27
US10258611B2 (en) 2019-04-16
KR102462638B1 (ko) 2022-11-03
US20170360762A1 (en) 2017-12-21
US20210000804A1 (en) 2021-01-07
US20200030301A1 (en) 2020-01-30
KR20170086058A (ko) 2017-07-25
CA2967826A1 (en) 2016-06-02
CN107205986A (zh) 2017-09-26
JP6827924B2 (ja) 2021-02-10
EP3223815A4 (en) 2018-06-27
WO2016085998A1 (en) 2016-06-02
EP3223815B1 (en) 2021-07-28
US11278531B2 (en) 2022-03-22
EP3223815A1 (en) 2017-10-04
BR112017010700A2 (pt) 2018-05-08

Similar Documents

Publication Publication Date Title
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
EP1696904B1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
EP1727539B1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
JP2012528818A (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
KR101335118B1 (ko) 비만 세포 매개 질환의 치료를 위한 １-아미노-알킬시클로헥산 유도체
UA65542C2 (uk) Спосіб пригнічення надлишкового продукування фактора некрозу пухлин альфа , спосіб полегшення шкідливих ефектів надлишкового продукування фактора некрозу пухлин альфа та спосіб лікування запального стану або захворювання, пов'язаного з фактором некрозу пухлин.
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
HK1247847A1 (zh) 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
WO2019018247A1 (en) USE OF AMBROXOL TO IMPROVE AND / OR EXTEND THE LIFETIME IN GOOD HEALTH, LIFETIME AND / OR MENTAL ACUITY
US20240299407A1 (en) Alpha-1062 for treating traumatic brain injury
JP2025134852A (ja) 創薬のためのヒトスフェロイドの使用方法
US20150366847A1 (en) Combination of geranylgeranylacetone and ibudilast and methods of using same
WO2016086000A1 (en) A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
US9851354B2 (en) Methods of treating fragile X syndrome and related disorders
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
CN118356415B (zh) 一种替曲朵辛口膜制剂及其制备和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201111

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930